Continuous Versus Flash Glucose Monitoring To Reduce Hypoglycemia In Type 1 Diabetes
Continuous glucose monitoring may reduce hypoglycemia fear.
The Dexcom G5 system was approved by the FDA in 2016 and was later permitted for use to replace finger-stick testing to determine insulin dose. The REPLACE-BG study proved its safety and effectiveness in adults with well-controlled type 1 diabetes at low risk for severe hypoglycemia. The FreeStyle Libre Pro System was also approved last year by the US FDA for use by physicians for monitoring glucose in patients with diabetes. It is the third “blinded” professional CGM system on the US market, joining the Dexcom G4 Platinum Professional Real-Time CGM and the Medtronic iPro2 Professional CGM, but it does not require finger-stick calibration, has no reusable components requiring disinfection, provides a longer period of data capture (14 days, compared with 7 for the Dexcom and 3 for Medtronic), and has a lower cost.
Previously studies revealed that CGMs could increase the time spent in and above glucose target range along with reduction in time below that same range in type 1 diabetes. Almost one-fourth of the adult patients had experienced reduction in awareness of hypoglycemia putting them at high-risk for severe hypoglycemia. In a recent UK study, real-time continuous glucose monitoring (CGM) has shown significant improvement in identifying and reducing the time spent in hypoglycemia in comparison to the flash glucose monitoring (FGM) in type 1 diabetes patients with impaired hypoglycemia awareness. According to Dr. Monika Reddy, the study showed that both CGM and FGM devices: G5 by Dexcom and Freestyle Libre b Continue reading